Physician profile
Amanda Sanchez
NPI 1568913234
$5,320.42
in general payments reported to CMS, 2019-2025
28 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $787 · 2022: $872 · 2023: $1,004 · 2024: $1,411 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,652 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,652.21 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,031.39 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lumenis Be INC | $1,001.73 | 2024 | M22 |
| Lilly USA, LLC | $679.61 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $482.05 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $452.88 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $274.55 | 2021-2025 | |
| Pfizer INC. | $231.72 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.03 | 2021-2025 | Jardiance |
| Amgen INC. | $167.89 | 2022-2025 | Otezla, Repatha |
| Mayne Pharma Commercial LLC | $145.23 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.38 | 2021-2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $88.17 | 2022 | |
| Novartis Pharmaceuticals Corporation | $55.51 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $51.46 | 2021 | |
| Exact Sciences Corporation | $48.86 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $41.92 | 2023-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $36.29 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $32.79 | 2025 | |
| Esperion Therapeutics, INC. | $30.96 | 2021-2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $26.25 | 2021-2022 | |
| Corcept Therapeutics | $23.58 | 2025 | Korlym |
| Hologic Sales and Service, LLC | $22.54 | 2024 | Aptima |
| Amarin Pharma, INC. | $21.64 | 2022 | |
| Astellas Pharma US INC | $21.06 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $18.08 | 2022 | |
| Exeltis, USA INC. | $17.82 | 2025 | Slynd |
| Organon LLC | $12.73 | 2022 | |
| Genentech USA, INC. | $4.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.